Beigene Ltd., of Beijing, signed an agreement with Celgene Corp., of Summit, N.J., to terminate the parties' global collaboration for tislelizumab, Beigene's investigational anti-PD-1 antibody, in advance of the pending acquisition of Celgene by Bristol-Myers Squibb Co., of New York. In connection with the termination, Celgene has agreed to pay $150 million to Beigene.